AnaptysBio (ANAB) News Today $20.31 +0.34 (+1.70%) (As of 11/20/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Truist Financial Sticks to Its Hold Rating for AnaptysBio (ANAB)November 20 at 1:14 PM | markets.businessinsider.comAnaptysBio, Inc. (NASDAQ:ANAB) Receives $54.64 Consensus Price Target from BrokeragesNovember 20 at 1:57 AM | americanbankingnews.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Rating of "Moderate Buy" by AnalystsShares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twelve brokerages that are covering the firm, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and ten have given a buy ratiNovember 17, 2024 | marketbeat.comBroker Revenue Forecasts For AnaptysBio, Inc. (NASDAQ:ANAB) Are Surging HigherNovember 16, 2024 | finance.yahoo.comAnaptysBio's (ANAB) Outperform Rating Reaffirmed at WedbushNovember 16, 2024 | americanbankingnews.comTD Cowen Reaffirms Their Buy Rating on AnaptysBio (ANAB)November 15, 2024 | markets.businessinsider.comJPMorgan Chase & Co. Cuts AnaptysBio (NASDAQ:ANAB) Price Target to $66.00November 15, 2024 | americanbankingnews.comAnaptysBio price target lowered to $66 from $75 at JPMorganNovember 12, 2024 | markets.businessinsider.comAnaptysBio (NASDAQ:ANAB) Given New $66.00 Price Target at JPMorgan Chase & Co.JPMorgan Chase & Co. lowered their target price on shares of AnaptysBio from $75.00 to $66.00 and set an "overweight" rating for the company in a report on Tuesday.November 12, 2024 | marketbeat.comFY2024 EPS Estimates for AnaptysBio Boosted by HC WainwrightAnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Equities research analysts at HC Wainwright boosted their FY2024 earnings estimates for AnaptysBio in a research note issued to investors on Wednesday, November 6th. HC Wainwright analyst E. Bodnar now expects that the biotechnology company will postNovember 8, 2024 | marketbeat.comAnaptysBio FY2024 EPS Forecast Raised by Leerink PartnrsAnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at Leerink Partnrs boosted their FY2024 earnings per share (EPS) estimates for AnaptysBio in a note issued to investors on Tuesday, November 5th. Leerink Partnrs analyst D. Risinger now expects that the biotechnology company willNovember 8, 2024 | marketbeat.comWhat is Wedbush's Forecast for AnaptysBio FY2024 Earnings?AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) - Investment analysts at Wedbush increased their FY2024 earnings per share estimates for AnaptysBio in a report issued on Tuesday, November 5th. Wedbush analyst D. Nierengarten now forecasts that the biotechnology company will earn ($5.22) per share foNovember 8, 2024 | marketbeat.comBuy Rating for AnaptysBio Driven by ANB032 Potential and Diversified PipelineNovember 7, 2024 | markets.businessinsider.comStifel Nicolaus Keeps Their Buy Rating on AnaptysBio (ANAB)November 7, 2024 | markets.businessinsider.comAnaptysBio: Promising Pipeline and Strong Cash Reserves Underscore Buy Rating Despite Recent Stock DeclineNovember 7, 2024 | markets.businessinsider.comAnaptysBio: Strong Financials, Promising Pipeline, and Key Catalysts Undervalue Market PositionNovember 7, 2024 | markets.businessinsider.comAnaptysBio's (ANAB) Outperform Rating Reiterated at WedbushWedbush reiterated an "outperform" rating and issued a $42.00 target price on shares of AnaptysBio in a report on Wednesday.November 6, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Shares Gap Up After Strong EarningsAnaptysBio (NASDAQ:ANAB) Shares Gap Up Following Better-Than-Expected EarningsNovember 6, 2024 | marketbeat.comAnaptys Announces Third Quarter 2024 Financial Results and Provides Business UpdateNovember 5, 2024 | globenewswire.comAnaptys Announces Participation in November and December Investor ConferencesNovember 5, 2024 | globenewswire.comAnaptysBio (ANAB) Gets a Buy from BTIGNovember 5, 2024 | markets.businessinsider.comAnaptysBio (ANAB) Gets a Hold from Truist FinancialNovember 4, 2024 | markets.businessinsider.comAnaptysBio (NASDAQ:ANAB) Stock Price Down 5.4% - Should You Sell?AnaptysBio (NASDAQ:ANAB) Trading Down 5.4% - What's Next?November 4, 2024 | marketbeat.comAnaptysBio: Too Risky, Especially After GSK Drops Its Related ProgramsNovember 1, 2024 | seekingalpha.comAnaptysBio's (ANAB) "Buy" Rating Reaffirmed at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $55.00 price objective on shares of AnaptysBio in a research report on Thursday.October 31, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Stock, Option ChainOctober 31, 2024 | benzinga.comOptimistic Outlook for AnaptysBio’s Rosnilimab Amid Distinctive Efficacy in Phase 2 TrialsOctober 31, 2024 | markets.businessinsider.comOptimistic Buy Rating for AnaptysBio Driven by Promising Immunotherapy Pipeline and Market PotentialOctober 31, 2024 | markets.businessinsider.comAnaptysBio weakness on competitor news a buying opportunity, says GuggenheimOctober 30, 2024 | markets.businessinsider.comAnaptysBio plunges as Eli Lilly drops arthritis drug from pipelineOctober 30, 2024 | msn.comAnaptysBio sinks 30% after Lilly slides show PD-1 agonist pulledOctober 30, 2024 | markets.businessinsider.comAnaptysBio (NASDAQ:ANAB) Shares Gap Down - What's Next?AnaptysBio (NASDAQ:ANAB) Shares Gap Down - Time to Sell?October 30, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) PT Raised to $33.00UBS Group increased their target price on shares of AnaptysBio from $23.00 to $33.00 and gave the stock a "neutral" rating in a research report on Wednesday.October 30, 2024 | marketbeat.comAssenagon Asset Management S.A. Grows Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)Assenagon Asset Management S.A. boosted its holdings in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 55.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 475,446 shares of the biotechnology company's stock after purchasing an additional 168October 27, 2024 | marketbeat.comPiper Sandler Keeps Their Buy Rating on AnaptysBio (ANAB)October 25, 2024 | markets.businessinsider.comAnaptysBio (NASDAQ:ANAB) Stock Price Down 6.9% - Here's WhyAnaptysBio (NASDAQ:ANAB) Stock Price Down 6.9% - Time to Sell?October 25, 2024 | marketbeat.comAnaptysBio’s Promising Therapeutic Agonist Pipeline Garners Buy Rating from David RisingerOctober 25, 2024 | markets.businessinsider.comAnaptysBio, Inc. (NASDAQ:ANAB) Given Consensus Recommendation of "Moderate Buy" by AnalystsShares of AnaptysBio, Inc. (NASDAQ:ANAB - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the twelve brokerages that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold rating and ten have assigned a bOctober 23, 2024 | marketbeat.comA Glimpse Into The Expert Outlook On AnaptysBio Through 6 AnalystsOctober 23, 2024 | benzinga.comAnaptysBio (NASDAQ:ANAB) Given New $90.00 Price Target at GuggenheimGuggenheim raised their price target on shares of AnaptysBio from $75.00 to $90.00 and gave the company a "buy" rating in a report on Monday.October 21, 2024 | marketbeat.com“Buy” Rating for AnaptysBio Driven by Promising Preclinical Data on Rosnilimab’s Ulcerative Colitis Treatment PotentialOctober 16, 2024 | markets.businessinsider.comAnaptysBio (NASDAQ:ANAB) Shares Down 4.9% - Here's WhyAnaptysBio (NASDAQ:ANAB) Stock Price Down 4.9% - Here's WhyOctober 15, 2024 | marketbeat.comAnaptysBio (NASDAQ:ANAB) Trading 6.5% Higher - Still a Buy?AnaptysBio (NASDAQ:ANAB) Trading Up 6.5% - Should You Buy?October 14, 2024 | marketbeat.comAnaptysBio, Inc. (NASDAQ:ANAB) Shares Sold by Millennium Management LLCMillennium Management LLC cut its stake in shares of AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 42.2% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 373,762 shares of the biotechnology company's stockOctober 9, 2024 | marketbeat.comDimensional Fund Advisors LP Sells 133,926 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)Dimensional Fund Advisors LP reduced its holdings in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 28.5% in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 335,934 shares of the biotechnology company's stockOctober 8, 2024 | marketbeat.comPoint72 Asset Management L.P. Decreases Stock Holdings in AnaptysBio, Inc. (NASDAQ:ANAB)Point72 Asset Management L.P. lessened its holdings in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 97.9% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 17,900 shares of the biotechnology company's stock after selOctober 5, 2024 | marketbeat.comAnaptysBio shares hold as Piper Sandler keeps Overweight ratingOctober 4, 2024 | investing.comAnaptysBio (NASDAQ:ANAB) Shares Down 3.2% - Time to Sell?AnaptysBio (NASDAQ:ANAB) Trading Down 3.2% - Here's What HappenedOctober 4, 2024 | marketbeat.comPiper Sandler Sticks to Their Buy Rating for AnaptysBio (ANAB)October 3, 2024 | markets.businessinsider.comSusquehanna Fundamental Investments LLC Buys 17,855 Shares of AnaptysBio, Inc. (NASDAQ:ANAB)Susquehanna Fundamental Investments LLC lifted its position in AnaptysBio, Inc. (NASDAQ:ANAB - Free Report) by 32.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 72,060 shares of the biotechnology company's stock after purchasing an additioOctober 2, 2024 | marketbeat.com Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address When it comes to NVDA… “acceleration cycles” are the key (Ad)Expert options trader Graham Lindman has been working on a new way to tap into Nvidia’s options… By simply isolating outsized “acceleration cycles” within Nvidia stock (most investors don’t even know it exists)... And thanks to many months and late nights working out the kinks of the systems… They have finally found a way to target these cycles on Nvidia over and over again. Use this link to see Nvidia Unchained right away! ANAB Media Mentions By Week ANAB Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ANAB News Sentiment▼0.080.45▲Average Medical News Sentiment ANAB News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ANAB Articles This Week▼83▲ANAB Articles Average Week Get AnaptysBio News Delivered to You Automatically Sign up to receive the latest news and ratings for ANAB and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Twist Bioscience News Today Longboard Pharmaceuticals News Today Arrowhead Pharmaceuticals News Today Protagonist Therapeutics News Today IDEAYA Biosciences News Today NewAmsterdam Pharma News Today CG Oncology News Today Keros Therapeutics News Today Wave Life Sciences News Today Akero Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ANAB) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AnaptysBio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AnaptysBio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ANAB Stock Alerts